NO2789793T3 - - Google Patents

Info

Publication number
NO2789793T3
NO2789793T3 NO14172620A NO14172620A NO2789793T3 NO 2789793 T3 NO2789793 T3 NO 2789793T3 NO 14172620 A NO14172620 A NO 14172620A NO 14172620 A NO14172620 A NO 14172620A NO 2789793 T3 NO2789793 T3 NO 2789793T3
Authority
NO
Norway
Application number
NO14172620A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO2789793T3 publication Critical patent/NO2789793T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO14172620A 2012-10-24 2012-04-24 NO2789793T3 (enExample)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261717743P 2012-10-24 2012-10-24

Publications (1)

Publication Number Publication Date
NO2789793T3 true NO2789793T3 (enExample) 2018-01-27

Family

ID=49488609

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14172620A NO2789793T3 (enExample) 2012-10-24 2012-04-24

Country Status (19)

Country Link
US (1) US20150283259A1 (enExample)
EP (1) EP2911696B1 (enExample)
JP (1) JP6328649B2 (enExample)
KR (1) KR20150085808A (enExample)
CN (1) CN104755106B (enExample)
AU (1) AU2013336410B2 (enExample)
BR (1) BR112015008311A2 (enExample)
CA (1) CA2884359A1 (enExample)
DK (1) DK2911696T3 (enExample)
ES (1) ES2652513T3 (enExample)
HU (1) HUE037604T2 (enExample)
IL (1) IL237673A0 (enExample)
IN (1) IN2015DN02577A (enExample)
MX (1) MX2015005124A (enExample)
NO (1) NO2789793T3 (enExample)
RU (1) RU2015119557A (enExample)
SG (1) SG11201501955VA (enExample)
WO (1) WO2014064424A1 (enExample)
ZA (1) ZA201501996B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014233385C1 (en) 2013-03-15 2019-09-19 Regeneron Pharmaceuticals, Inc. Biologically active molecules, conjugates thereof, and therapeutic uses
WO2014194030A2 (en) * 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
KR102252925B1 (ko) 2013-08-26 2021-05-18 리제너론 파마슈티칼스 인코포레이티드 마크롤라이드 디아스테레오머를 포함하는 약제학적 조성물, 이의 합성 방법 및 치료학적 용도
ES2792598T3 (es) * 2014-05-23 2020-11-11 Novartis Ag Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
HK1231367A1 (zh) 2014-06-02 2017-12-22 Regeneron Pharmaceuticals, Inc. 抗体药物偶联物、试剂和制备方法及其治疗用途
GB2531715A (en) * 2014-10-24 2016-05-04 Polytherics Ltd Novel drug conjugates
EP3218009B1 (en) 2014-10-14 2021-04-07 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
WO2016063006A1 (en) * 2014-10-24 2016-04-28 Polytherics Limited Conjugates and conjugating reagents
KR20240142591A (ko) 2015-03-27 2024-09-30 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 이의 컨주게이트, 및 사용 방법
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3331569A1 (en) * 2015-08-07 2018-06-13 Gamamabs Pharma Antibodies, antibody drug conjugates and methods of use
KR102885186B1 (ko) 2016-01-25 2025-11-17 리제너론 파아마슈티컬스, 인크. 메이탄시노이드 유도체, 그의 접합체, 및 사용 방법
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
WO2017178828A1 (en) 2016-04-14 2017-10-19 Polytherics Limited Conjugates and conjugating reagents comprising a linker that includes at least two (-ch2-ch2-0-) units in a ring
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
US11485792B2 (en) 2016-06-06 2022-11-01 Polytherics Limited Antibodies, uses thereof and conjugates thereof
GB201614162D0 (en) 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
GB201615725D0 (en) * 2016-09-15 2016-11-02 Polytherics Ltd Novel cytotoxic agents and conjugates thereof
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体,含有此连接体的细胞结合分子-药物偶联物及其制备和应用
US10864279B2 (en) 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
CN114040778A (zh) 2019-06-29 2022-02-11 杭州多禧生物科技有限公司 一种细胞结合分子-Tubulysin衍生物偶联物及其制备方法
US11918649B2 (en) 2019-09-18 2024-03-05 Molecular Templates, Inc. PD-L1-binding molecules comprising Shiga toxin a subunit scaffolds
EP4208259A2 (en) 2020-09-04 2023-07-12 NovaRock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
EP4308242A1 (en) 2021-03-17 2024-01-24 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
CN117147824A (zh) * 2022-05-29 2023-12-01 菲鹏生物股份有限公司 一种抗体缀合物及其应用
CN119161461A (zh) * 2023-06-19 2024-12-20 广东菲鹏生物有限公司 标记Fab抗体
WO2026020031A2 (en) 2024-07-18 2026-01-22 Novarock Biotherapeutics, Ltd. Cdh17 antibodies and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
CN107213469A (zh) * 2003-11-06 2017-09-29 西雅图基因公司 能够与配体偶联的单甲基缬氨酸化合物
EP1940470B1 (en) * 2005-09-26 2013-04-17 Medarex, Inc. Antibody-drug conjugates and their use
DK2211904T3 (en) * 2007-10-19 2016-10-24 Seattle Genetics Inc Cd19-binding agents and uses thereof
CN102083461B (zh) * 2008-04-30 2014-09-17 伊缪诺金公司 有效的偶联物和亲水性连接体
EP2403538B1 (en) 2009-03-04 2017-10-04 Polytherics Limited Conjugated proteins and peptides
TW201117814A (en) 2009-10-02 2011-06-01 Sanofi Aventis New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
AU2013279099A1 (en) * 2012-06-19 2014-12-18 Polytherics Limited Novel process for preparation of antibody conjugates and novel antibody conjugates

Also Published As

Publication number Publication date
AU2013336410A1 (en) 2015-04-09
SG11201501955VA (en) 2015-04-29
US20150283259A1 (en) 2015-10-08
ES2652513T3 (es) 2018-02-02
WO2014064424A1 (en) 2014-05-01
CA2884359A1 (en) 2014-05-01
CN104755106A (zh) 2015-07-01
EP2911696A1 (en) 2015-09-02
RU2015119557A (ru) 2016-12-20
KR20150085808A (ko) 2015-07-24
ZA201501996B (en) 2016-01-27
JP2015536329A (ja) 2015-12-21
JP6328649B2 (ja) 2018-05-23
EP2911696B1 (en) 2017-09-20
IL237673A0 (en) 2015-04-30
HK1208186A1 (en) 2016-02-26
CN104755106B (zh) 2018-03-13
IN2015DN02577A (enExample) 2015-09-11
MX2015005124A (es) 2015-10-29
HUE037604T2 (hu) 2018-09-28
BR112015008311A2 (pt) 2017-07-04
AU2013336410B2 (en) 2017-08-03
DK2911696T3 (en) 2018-01-08

Similar Documents

Publication Publication Date Title
BR112014023459A2 (enExample)
BR112014017635A2 (enExample)
BR112014017614A2 (enExample)
BR112014017625A2 (enExample)
BR112014017592A2 (enExample)
BR112014017607A2 (enExample)
BR112014017646A2 (enExample)
NO2789793T3 (enExample)
BR112014017638A2 (enExample)
AR092201A1 (enExample)
BR112013027865A2 (enExample)
BR112014017609A2 (enExample)
BR112014017644A2 (enExample)
BR112014017634A2 (enExample)
BR112014018863A2 (enExample)
BR112014017588A2 (enExample)
BR112014013184A8 (enExample)
BR112014017618A2 (enExample)
BR112014017647A2 (enExample)
BR112014017627A2 (enExample)
BR112014017623A2 (enExample)
BR112014017652A2 (enExample)
BR112014017630A2 (enExample)
BR112014017621A2 (enExample)
BR112014017631A2 (enExample)